BACKGROUND AND PURPOSE: Multiple sclerosis (MS) is a demyelinating disease most often associated with progressive physical impairment; however, its effects are noted to extend beyond physical disability. Our purpose was to determine the relationship between T2 lesion volume and neurocognitive and physical disability in relapsing-remitting multiple sclerosis. METHODS: We studied a cohort of 19 patients with relapsing-remitting MS. Of this group, there were 15 women and four men from varying socioeconomic backgrounds. This volunteer sample was selected from a larger group of 53 patients with MS in our longitudinal MS study because they had been untreated with any beta-interferon medications, had been followed for at least 12 months, and had a clinical status of relapsing-remitting MS. RESULTS: Of 12 neurocognitive parameters tested, two correlated significantly with lesion loads. The correlation of the Symbol-Digit Modalities test, which analyzes information-processing speed, was significant (P = .0204). The correlation of the fifth trial of the Rey Auditory Verbal Learning test, which tests verbal long-term memory, was also significant (P = .0348). None of the other 10 neurocognitive examinations, however, showed a significant correlation with total lesion volume (Paced Auditory Serial Addition test-1.6, P = .7381; Paced Auditory Serial Addition test-2.0, P = .4180; Controlled Oral Word Association test, P = .8906; Category Fluency test, P = .4423; Bells test, P = .9097; Rey Auditory Verbal Learning test-delay, P = .9843, Rey Auditory Verbal Learning test-recognition, P = .7467; Word Span test, P = .4939; Road Map test, P = 0.4939). The lesion load also did not correlate with the physical disability scales as rated according to the Expanded Disability Status Scale (P = .68) or Ambulation Index (P = .95). CONCLUSION: Our results indicate that T2 lesion volume does not seem to be a robust surrogate marker of neuropsychological impairment in patients with MS. We think that global measurements of parameters that are more specific to the disease process may offer more precise correlation with cognitive dysfunction and other disability parameters.
BACKGROUND AND PURPOSE:Multiple sclerosis (MS) is a demyelinating disease most often associated with progressive physical impairment; however, its effects are noted to extend beyond physical disability. Our purpose was to determine the relationship between T2 lesion volume and neurocognitive and physical disability in relapsing-remitting multiple sclerosis. METHODS: We studied a cohort of 19 patients with relapsing-remitting MS. Of this group, there were 15 women and four men from varying socioeconomic backgrounds. This volunteer sample was selected from a larger group of 53 patients with MS in our longitudinal MS study because they had been untreated with any beta-interferon medications, had been followed for at least 12 months, and had a clinical status of relapsing-remitting MS. RESULTS: Of 12 neurocognitive parameters tested, two correlated significantly with lesion loads. The correlation of the Symbol-Digit Modalities test, which analyzes information-processing speed, was significant (P = .0204). The correlation of the fifth trial of the Rey Auditory Verbal Learning test, which tests verbal long-term memory, was also significant (P = .0348). None of the other 10 neurocognitive examinations, however, showed a significant correlation with total lesion volume (Paced Auditory Serial Addition test-1.6, P = .7381; Paced Auditory Serial Addition test-2.0, P = .4180; Controlled Oral Word Association test, P = .8906; Category Fluency test, P = .4423; Bells test, P = .9097; Rey Auditory Verbal Learning test-delay, P = .9843, Rey Auditory Verbal Learning test-recognition, P = .7467; Word Span test, P = .4939; Road Map test, P = 0.4939). The lesion load also did not correlate with the physical disability scales as rated according to the Expanded Disability Status Scale (P = .68) or Ambulation Index (P = .95). CONCLUSION: Our results indicate that T2 lesion volume does not seem to be a robust surrogate marker of neuropsychological impairment in patients with MS. We think that global measurements of parameters that are more specific to the disease process may offer more precise correlation with cognitive dysfunction and other disability parameters.
Authors: J Foong; L Rozewicz; G Quaghebeur; C A Davie; L D Kartsounis; A J Thompson; D H Miller; M A Ron Journal: Brain Date: 1997-01 Impact factor: 13.501
Authors: G Comi; M Filippi; V Martinelli; A Campi; M Rodegher; M Alberoni; G Sirabian; N Canal Journal: J Neurol Sci Date: 1995-10 Impact factor: 3.181
Authors: G Sinson; L J Bagley; K M Cecil; M Torchia; J C McGowan; R E Lenkinski; T K McIntosh; R I Grossman Journal: AJNR Am J Neuroradiol Date: 2001-01 Impact factor: 3.825
Authors: M S A Deloire; E Salort; M Bonnet; Y Arimone; M Boudineau; H Amieva; B Barroso; J-C Ouallet; C Pachai; E Galliaud; K G Petry; V Dousset; C Fabrigoule; B Brochet Journal: J Neurol Neurosurg Psychiatry Date: 2005-04 Impact factor: 10.154
Authors: R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon Journal: J Neurol Neurosurg Psychiatry Date: 2001-06 Impact factor: 10.154
Authors: M R Piras; I Magnano; E D G Canu; K S Paulus; W M Satta; A Soddu; M Conti; A Achene; G Solinas; I Aiello Journal: J Neurol Neurosurg Psychiatry Date: 2003-07 Impact factor: 10.154